The ARRY sewer pipeline is clogged. What the sewer pipeline is clogged with is what one would expect in a sewer pipe. After all how long can projects like ErB, KSP, and P38 continue in Phase I without communication of results to the investors. For these “turds” I believe that it was easier for ARRY not to say anything about failures, rather keep them stagnant in the sewer pipeline.

The key to the efficacy of a compound is it’s chemical structure. What is the chemical structure of ARRY-162 versus ARRY-886 (Failed phase 2 in cancer trials)? How different is the glucokinase ionhibitor’s chemical structure from the competition? Be good investors and find the answer to these questions and you shall find the truth. Poster sessions at conferences are a great resource for this information. I found the truth and was a invested in ARRY for over 6 years (started investing with ARRY in the beginning). After finding the truth I cashed out at $13 and will always be thankful to ARRY and its investors.

The key to ARRY’s future is to sift through the sewage find the one potential diamond, cut it polish it through clinical trials, funded by cashing in on its current resources.